Searched for
SYNGENE MD
Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...- Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...
- Syngene Q4 Results: Profit dips 3% to Rs 183 crore; FY25 net at Rs 496 crContract research and manufacturing services firm Syngene International on Wednesday reported a 3 per cent dip in consolidated net profit a...
- Syngene's MD & CEO Jonathan Hunt steps down, Peter Bains named as new CEOJonathan Hunt has stepped down as the managing director and CEO of Syngene International, with Peter Bains appointed as the CEO Designate e...
- Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 croreSyngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...
- Syngene Q4 Results: Net profit rises 6% to Rs 189 crore, revenue drops 8%The earnings before interest, tax, depreciation and ammortisation dropped 1% YoY to Rs. 333 crore in Q4FY24. The EBITDA margin rose 300 bas...
- Syngene International Q3 Results: Net profit rises 2% YoY to Rs 112 crore, company revises revenue guidanceThe rise in Q3 profit of Syngene International was led by dedicated centres and development and manufacturing services, even as discovery s...
- Syngene Q2 Results: Net profit jumps 14% to Rs 117 croreNet profit before an exceptional item rose 20% YoY to 122 crore. The exceptional item pertains to transaction costs relating to the acquisi...
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...
- Syngene International Q1 Results: Net profit jumps 26% to Rs 93 croreThe first quarter revenue from operations rose 26% YoY to Rs. 832 crore. The earnings before interest, tax, depreciation and ammortisation ...
- Syngene International sees strong momentum this fiscal year: MDSyngene International also expects business growth from its pharma clients who are keen to make up for the time that they felt they lost du...
- Syngene International Q4 Results: Net profit jumps 21% to YoY Rs 179 croreHunt said the manufacturing services had a particularly strong year, led by the commercial-scale biologics manufacturing business, which ha...
- Hyderabad emerging as life sciences hub, with global and domestic pharmaceutical firms"The Government of Telangana is committed to providing an inspiring ecosystem for the growth of the life sciences industry as illustrated b...
- Syngene to benefit from rupee depreciation, rising demand for research & manufacturing services: CEO Jonathan HuntSyngene has raised the revenue guidance for FY23 from mid-teens to high teens due to significant depreciation of rupee against the dollar a...
- Seeing good demand for biologics manufacturing: Syngene CEO Jonathan HuntIn an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of micro...
- Syngene International Q1 results: Net profit rises 33% to Rs 77 cr; John Shaw to step down from boardConsolidated revenue from operations of the company stood at Rs 594.5 crore for the quarter under consideration. It was Rs 421.6 crore for ...
- Syngene International Q3 results: Profit rises 11% to Rs 102 crRevenue from the operations stood at Rs 585 crore in the quarter under review. It was Rs 519 crore in December quarter 2019-20, it added.
- Syngene International Q4 results: Profit up 20% to Rs 120 croreThe company had posted a net profit of Rs 100 crore for the corresponding period of the previous fiscal.
- Syngene appoints Jonathan Hunt as CEO-designateHunt will take charge after the retirement of current CEO Peter Bains in March, Syngene International said in a regulatory filing.
- Biocon to sell up to 25% in Syngene via IPOBiocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.
Load More
